Precision BioSciences (NASDAQ:DTIL) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Precision BioSciences (NASDAQ:DTIL) from a hold rating to a sell rating in a research report released on Saturday.

A number of other equities research analysts have also recently commented on DTIL. HC Wainwright reaffirmed a “buy” rating on shares of Precision BioSciences in a research note on Monday, August 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Precision BioSciences in a research note on Wednesday. JonesTrading restated a “buy” rating and set a $30.00 target price on shares of Precision BioSciences in a report on Friday, April 17th. Finally, Oppenheimer assumed coverage on Precision BioSciences in a research report on Tuesday, June 9th. They set an “outperform” rating and a $20.00 target price for the company. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $32.25.

Precision BioSciences Price Performance

Shares of DTIL stock opened at $7.49 on Friday. The firm’s 50 day moving average price is $7.36 and its two-hundred day moving average price is $6.33. The company has a debt-to-equity ratio of 0.29, a quick ratio of 14.02 and a current ratio of 14.02. Precision BioSciences has a 52-week low of $3.53 and a 52-week high of $9.62. The stock has a market cap of $193.26 million, a PE ratio of -2.67 and a beta of 1.27.

Precision BioSciences (NASDAQ:DTIL) last issued its earnings results on Thursday, August 6th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.46). Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 67.70%. As a group, analysts forecast that Precision BioSciences will post -2.6 EPS for the current year.

Institutional Trading of Precision BioSciences

Large investors have recently made changes to their positions in the company. Geode Capital Management LLC raised its stake in Precision BioSciences by 5.5% during the 2nd quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock worth $326,000 after buying an additional 4,025 shares during the period. Miller Financial Services LLC increased its holdings in shares of Precision BioSciences by 50.0% in the fourth quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock worth $62,000 after acquiring an additional 5,000 shares in the last quarter. Lynx1 Capital Management LP increased its holdings in shares of Precision BioSciences by 0.6% in the third quarter. Lynx1 Capital Management LP now owns 1,042,596 shares of the company’s stock worth $5,755,000 after acquiring an additional 6,545 shares in the last quarter. Quarry LP raised its position in shares of Precision BioSciences by 15.1% during the fourth quarter. Quarry LP now owns 68,311 shares of the company’s stock worth $284,000 after purchasing an additional 8,936 shares during the period. Finally, HBK Sorce Advisory LLC acquired a new stake in shares of Precision BioSciences during the fourth quarter worth about $38,000. Institutional investors own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.